Developing a new treatment for Alzheimer's Disease
Official title: Paving the Way to Phase 2 Trials of CMS121 for Alzheimer's Disease
Funded at Virogenics, INC. · NIH-11008209 · Data updated 2026-11-12
This study is testing a new drug called CMS121 that could help improve memory and thinking skills in people with Alzheimer's Disease, offering a different approach than current treatments, and it might make a real difference if it works well in trials.
Quick facts
| Grant type | Sbir 2 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Virogenics, INC. NIH-funded |
| Lab location | 1 site (Del Mar, United States) |
| Project start | September 30, 2024 |
| Project end | August 31, 2025 |
| Funding year | 2024 |
| Award (this year) | $2,432,649 |
| NIH project number | 1R44AG085775-01A1 |
| Project ID | NIH-11008209 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are adults aged 21 and older who are diagnosed with Alzheimer's Disease or exhibit symptoms of age-related cognitive decline.
✕Less likely to help
Patients with other forms of dementia or cognitive impairment unrelated to Alzheimer's Disease may not benefit from this research.
What this research studies
This research focuses on CMS121, a novel drug candidate for Alzheimer's Disease (AD) that aims to improve memory and executive function in patients. Unlike existing treatments that primarily target amyloid plaques, CMS121 interacts with different biological targets to potentially modify the disease's progression. The drug has shown promise in preclinical models by preventing and reversing cognitive decline associated with AD. Patients may benefit from this innovative approach if the drug proves effective in clinical trials.
Why it matters
Potential benefit: If successful, this research could lead to a new treatment that significantly improves cognitive function and quality of life for individuals with Alzheimer's Disease.
How similar studies have gone: While many Alzheimer's treatments have failed, the novel approach of CMS121 offers a unique perspective that has not been extensively tested in clinical settings, making it a potentially groundbreaking effort.
Where this research is happening
-
Virogenics, INC.
Del Mar, United States Active
Researchers
- Principal investigator: Raschke, William C — Virogenics, INC.
- Study coordinator: Raschke, William C
Related research
Other NIH-funded projects on the same topics.
-
Understanding how brain activity changes may drive Alzheimer’s disease progression in a mouse model
Researchers are testing how changes in brain signals and protein cleanup processes affect the development of Alzheimer’s disease in mice.
-
Thiamine-boosting therapy for Alzheimer’s: understanding how benfotiamine may reduce harmful AGE in DP patients
A medication-based approach using high-dose vitamin B1 (benfotiamine) is studied to help people with Alzheimer's by reducing harmful sugar-related molecules.
-
Non-invasive tears biomarker for early Alzheimer's in LMICs
A low-cost, tear-based biomarker approach aims to detect early Alzheimer’s disease in older adults in Peru and similar settings.
-
Turning APOE4 into protective APOE2 or APOE3Christchurch to help with Alzheimer’s
A patient-facing explanation of a treatment idea that aims to change a genetic risk factor for Alzheimer's disease in the brain.
-
Telomerase in Alzheimer’s Disease: how aging biology could influence memory and brain health
Researchers are exploring a new brain-aging mechanism linked to telomerase, with potential to slow or modify Alzheimer’s disease in people and improve cognitive function.
-
Biomarkers of Alzheimer’s Disease: Sensory, Motor, and Cognitive Clues
Researchers are testing simple sensory and movement tasks to find early signs of Alzheimer’s disease so they can diagnose and treat people sooner.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.